FORTE BIOSCIENCES FBRX 深 沪
等待开盘 09-10 09:30:00 美东时间
11.06
-0.070
-0.63%
华盛通- 最 高11.47
- 今 开11.47
- 成交量 7.43万股
- 最 低 10.7622
- 昨 收 11.13
- 总市值 1.38亿
- 52周最高 28.68
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 4.11
- 委 比 33.33%
- 总股本 1243.29万
- 历史最高 6732.375
- 量 比 1.47
- 振 幅 6.36%
- 历史最低 4.90
- 每 手 1
- 风险率 4.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FibroBiologics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
FibroBiologics, Inc., a clinical-stage biotech company developing therapies for chronic diseases using fibroblast cells, announced that CEO Pete O’Heeron will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8-10 in New York City. The company will deliver a presentation on September 10 at 12:00 p.m. ET and hold one-on-one investor meetings during the event. For more information, visit FibroBiologics’ website or...
08-27 12:30
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
08-15 20:11
Forte Biosciences Announces Public Offering of Shares
Forte Biosciences ( ($FBRX) ) just unveiled an update. On June 24, 2025, Forte ...
06-26 05:19
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Plus Therapeutics (NASDAQ:PSTV) stock increased by 66.2% to $0.31 duri...
06-26 01:06
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Forte Biosciences launches public offering
Forte Biosciences (NASDAQ:FBRX) has initiated an underwritten public offering of common stock and pre-funded warrants. Certain investors may receive pre-funded warrants instead of common stock. Underw...
06-25 04:16
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.
06-24 20:00
Forte Biosciences Reports Results in Celiac Disease Trial, Paving Way for Phase 2 in 2026
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac
06-23 19:20
Forte Biosciences Elects New Directors at Annual Meeting
Forte Biosciences ( ($FBRX) ) has provided an update. On May 29, 2025, Forte Bi...
05-30 20:58
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers SCWorx (NASDAQ:WORX) shares rose 60.0% to $0.64 during Tuesday's regul...
05-28 01:05
